EX-10.4



 Exhibit 10.4 

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT 

This Amendment No. 1 to Common Stock Purchase Agreement (this “Amendment”) is made as of May 4, 2015, by and
between Viking Therapeutics, Inc., a Delaware corporation (the “Company”), and Rochelle Hanley, M.D. (“Purchaser”). 

RECITALS 

WHEREAS, the Company and Purchaser are parties to that certain Common Stock Purchase Agreement, made as
of April 15, 2013 (the “Purchase Agreement”) pursuant to which the Company issued and sold to Purchaser, and Purchaser purchased from the Company, an aggregate of 250,000 shares (the “Purchased
Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”); 

WHEREAS, pursuant to that certain Amended and Restated Stock Repurchase Agreement, dated as of
April 28, 2015, by and among the Company, Purchaser, Brian Lian, Ph.D., Michael Dinerman, M.D., and Isabelle Dinerman, the Company repurchased from Purchaser an aggregate of 158,453 of the Purchased Shares at a repurchase price of $0.00001 per
share on the date hereof (the “Share Repurchase”); 
 WHEREAS, the Company and
Purchaser desire to amend the Purchase Agreement to reflect the vesting schedule for Purchaser’s outstanding unvested Vesting Shares after giving effect to the Share Repurchase; and 

WHEREAS, pursuant to Section 11(c) of the Purchase Agreement, no modification or amendment to the
Purchase Agreement shall be effective unless in writing signed by the parties to the Purchase Agreement. 
 NOW
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows: 

ARTICLE 1 
 AMENDMENT 

1.1 AMENDMENT TO SECTION 4(C) OF THE PURCHASE AGREEMENT. The second sentence of Section 4(c) of the Purchase Agreement is hereby
amended and restated in its entirety as follows: 
 “Of the Vesting Shares, (a) 62,500 shall be released on the earlier to occur
of (i) April 15, 2014 and (ii) the date the Company receives at least $25 million in gross financing proceeds from the sale of equity and/or debt securities of the Company, and (b) after giving effect to the repurchase of an
aggregate of 158,453 of the Shares by the Company from Purchaser pursuant to that certain Amended and Restated Stock Repurchase Agreement, dated as of April 28, 2015, by and among the Company, Purchaser and the other parties named therein (as
may be amended or restated from time to time), (i) 22,887 shall be released on April 15, 2016, and (ii) 22,886 shall be released on April 15, 2017; provided, however, that in each case such scheduled release from
the Repurchase Option shall immediately cease as of the Termination Date.” 







 ARTICLE 2 

GENERAL PROVISIONS 
 2.1
CAPITALIZED TERMS. All capitalized terms in this Amendment, to the extent not otherwise defined herein, shall have the meaning assigned to them in the Purchase Agreement. 

2.2 CONTINUING EFFECTIVENESS. Except as modified by this Amendment, the Purchase Agreement shall remain in full force and effect and no party
by virtue of entering into this Amendment is waiving any rights it has under the Purchase Agreement, and once this Amendment is executed by the parties hereto, all references in the Purchase Agreement to “the Agreement” or “this
Agreement,” as applicable, shall refer to the Purchase Agreement as modified by this Amendment. 
 2.3 SUCCESSORS AND ASSIGNS. The
rights and benefits of this Amendment shall inure to the benefit of, and be enforceable by the Company and its successors and assigns. 

2.4 GOVERNING LAW. This Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 

2.5 COUNTERPARTS. This Amendment may be executed in one or two counterparts, including counterparts transmitted by facsimile or other
electronic transmission, each of which shall be deemed an original and all of which together shall constitute one instrument. 

[Signature Page Follows] 

  
 2 








 IN WITNESS WHEREOF, the
parties have executed this Amendment as of the date first above written. 
  

			
	THE COMPANY:
	
	 VIKING THERAPEUTICS, INC.,

a Delaware corporation

		
	By:		 /s/ Brian Lian, Ph.D.

	Name:		Brian Lian, Ph.D.
	Title:		CEO
	
	PURCHASER:
	
	 /s/ Rochelle Hanley, M.D.

	ROCHELLE HANLEY, M.D.